Effect of Tofogliflozin on Cardiac Function: Potential Link Between Ketone Bodies and the Heart

Eiji Kutoh

Abstract


This report describes the effect of tofogliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), on cardiac function and its related parameters including ketone bodies (acetoacetate and beta-hydroxybutyrate). One case received and two cases discontinued tofogliflozin. Changes of cardiometabolic parameters were compared at 3 months. A 65-year-old patient with decreased heart function received tofogliflozin 20 mg/day. Left ventricular ejection fraction (EF), functional shortening (%FS), or acetoacetate/beta-hydroxybutyrate levels were increased. A 68-year-old patient with normal heart function discontinued tofogliflozin 20 mg/day. EF, %FS or acetoacetate/beta-hydroxybutyrate levels were decreased. A 60-year-old patient with slightly decreased heart function discontinued tofogliflozin. No changes of EF, %FS, or acetoacetate/beta-hydroxybutyrate levels were noted. Taken together, these results suggest that ketone bodies and the heart function appear to be related (concomitant changes by tofogliflozin) and that tofogliflozin might have effects on cardiac function through modulating ketone bodies.




J Endocrinol Metab. 2017;7(3):94-97
doi: https://doi.org/10.14740/jem396e

Keywords


Tofogliflozin; SGLT2i; Cardiac function; Ketone bodies; Heart

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

DECLARATION: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!